Maria Isabel Cisneros

US Patent:

20130316400, Nov 28, 2013

Filed:

May 2, 2013

Appl. No.:

13/886226

Inventors:

Henry CHIOU - Encinitas CA, US
Jeffrey ROGERS - Escondido CA, US
Maria Isabel CISNEROS - San Marcos CA, US
Jingqiu LI - San Diego CA, US
Chao Yan LIU - Clarence Center NY, US
Meredith JONES - Chapel Hill NC, US

Assignee:

LIFE TECHNOLOGIES CORPORATION - Carlsbad CA

International Classification:

C07K 14/505

US Classification:

435 691

Abstract:

The present invention is directed generally to cell culture media (particularly serum free, non animal derived, and/or chemically defined media) which are useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells). According to the invention, such introduction can take place in the presence of said medium. Cells containing such introduced materials can then be cultured in the medium and the effect of the introduced materials on the cells can be measured or determined. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention also relates to compositions and kits useful for culturing and transforming/transfecting cells.

US Patent:

20220411419, Dec 29, 2022

Filed:

May 1, 2019

Appl. No.:

17/052930

Inventors:

- San Diego CA, US
Robert I. HIGUCHI - Solana Beach CA, US
Richard MARTIN - San Diego CA, US
Maria Isabel CISNEROS - San Diego CA, US

International Classification:

C07D 417/14
C07D 417/12
C07D 405/12
C07D 405/14
C07D 277/60

Abstract:

The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.